^
Association details:
| Biomarker: | ROS1 wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer
Published date:
08/08/2023
Excerpt:
In this report, we examined the efficacy of durvalumab for patients with locally advanced, unresectable NSCLC at our institution. In addition, we focused on its efficacy in patients with driver mutations....In this retrospective analysis, durvalumab consolidation therapy following definitive chemoradiotherapy had a tendency to improve median PFS(group A 664 days [436-1069, 95%CI] vs group B 377days [282-451, 95%CI] p=0.053). The subgroup analysis of patients without driver mutations of EGFR, ALK or ROS-1 showed statistically longer median PFS by durvalumab consolidation (695 days [575-NA, 95%CI] vs 382 days [282-488, 95%CI], p<0.05)....
